查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1950512

鎳鈦諾血管重組器械市場（按產品類型、應用和最終用戶分類），全球預測（2026-2032）

Nitinol Revascularization Device Market by Product Type, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，鎳鈦合金再灌注裝置市場規模將達到 20.4 億美元，到 2026 年將達到 22.6 億美元。預計到 2032 年將達到 42.5 億美元，複合年成長率為 11.01%。

關鍵市場統計數據
基準年 2025 20.4億美元
預計年份：2026年 22.6億美元
預測年份 2032 42.5億美元
複合年成長率 (%) 11.01%

鎳鈦合金再灌注裝置的策略性入門指南：概述其臨床作用、材料優勢以及影響其臨床應用的關鍵因素

由於其獨特的材料特性和持續的器械創新，鎳鈦合金再灌注裝置已從小眾解決方案發展成為各種血管專科的核心工具。形狀記憶和超彈性使其能夠貼合複雜的解剖結構，從而拓展了其臨床應用範圍，從冠狀動脈介入治療擴展到神經血管和周邊血管領域。因此，臨床醫生和採購團隊擴大從多個角度評估器械的選擇，包括輸送性、徑向強度、貼合度和長期血管相互作用。

技術進步、臨床證據要求和基於價值的支付訊號如何融合，將重塑鎳鈦合金器械系列的採用和創新

技術的融合、臨床指南的不斷更新以及對成本效益的重新關注，正在推動鎳鈦合金再灌注裝置領域發生變革性轉變。小型化和改進的輸送系統使得以往難以到達的解剖部位成為可能，而表面處理技術和藥物釋放型策略則縮小了自膨脹式裝置和球囊擴張型之間的性能差距。這些技術進步正在改變臨床醫師的選擇偏好，並開啟了幾年前還無法實現的全新手術方法。

2025 年美國關稅的累積營運和採購影響正在迫使供應鏈重新設計，商業性重點重新調整。

2025年美國關稅政策為鎳鈦合金再灌注裝置的製造商和採購商帶來了新的商業風險和營運調整。最直接的影響是，各機構需要重新評估籌資策略，權衡成本、供應連續性和替代來源的監管複雜性。許多相關人員採取的應對措施包括加快供應商資格認證流程和實現採購管道多元化，以減少對單一供應商的依賴。這導致人們更加重視供應商審核和品質認證的公正性。

基於細分的因素對產品開發、臨床應用和採購的影響，將設備類別適用性和最終用戶環境與策略重點連結起來。

了解鎳鈦合金再灌注治療領域的細分市場對於制定合適的臨床、商業性和監管策略至關重要。產品差異化始於兩大類器械：球囊擴張型支架和自擴張式鎳鈦合金支架。球囊擴張型支架主要用於冠狀動脈介入治療和周邊血管手術，在這些手術中，徑向剛度和精確部署至關重要。自擴張式鎳鈦合金支架則適用於神經血管和周邊血管解剖結構，這些部位需要支架具有柔軟性和長期的貼合性。在周邊血管手術中，膝下、股膕動脈和髂股動脈等不同血管的解剖結構和動態差異會影響器械的設計選擇、耐久性預測以及手術輔助工具的使用。

區域法規環境、臨床實踐模式和基礎設施現狀決定了最適合美洲、歐洲、中東和非洲以及亞太地區的商業化方法。

區域趨勢將顯著影響全球市場鎳鈦合金再灌注裝置的監管路徑、臨床應用和商業化策略。在美洲，法規結構已相當完善，支付者也越來越重視基於可靠的臨床結果和成本效益進行報銷。這迫使製造商優先考慮產生高品質的實證醫學證據並建立高效的經銷夥伴。在培訓和操作支援方面進行投入，通常是增強臨床醫生信心並將其融入心臟病學和血管外科治療路徑的關鍵因素。

從企業層面的競爭與合作觀點，著眼於技術差異化，展現了塑造市場定位的夥伴關係與營運能力。

鎳鈦合金再灌注領域的企業競爭體現在創新策略、臨床夥伴關係以及市場推廣的差異化。一些製造商專注於平台工程，整合新一代輸送系統和先進的影像相容性，以實現臨床療效的逐步提升和手術效率的提高。另一些製造商則優先考慮表面處理、藥物釋放型技術和聚合物整合，以解決血管再阻塞和長期血管癒合問題，這需要持續投入臨床試驗和上市後監測。

針對製造商、醫療系統和經銷商的具體策略：建立具有韌性的價值鏈，以加速臨床應用並向支付方證明其價值

產業領導者應採取一系列切實可行的舉措，將洞察轉化為臨床、商業和營運領域的競爭優勢。首先，應優先開發模組化平台，該平台能夠支援多種鎳鈦合金形式和治療適應症，並採用單一給藥系統，從而降低生產複雜性，減輕臨床醫生的培訓負擔。其次，應投資於有針對性的真實世界證據項目和註冊登記，以解答支付方最關心的問題，並產生持續醫保談判所需的長期安全性數據。

一種透明且可重複的調查方法，結合文獻綜述、專家訪談和供應鏈分析，以檢驗研究結果及其意義。

本分析所依據的研究採用了混合方法，以確保研究的穩健性、多方驗證和透明度。二手資料收集利用了同行評審的臨床文獻、監管文件和醫療設備認證摘要，以梳理臨床證據和核准途徑。專利格局分析和產品標籤審查確定了技術差異和主張依據，而公共採購文件和醫院採購政策則提供了有關定價和競標條款的見解。

綜合考慮臨床、技術和商業性因素，以確定哪些鎳鈦合金器械能夠獲得持續應用和策略優勢。

透過整合臨床進展、政策阻力和商業策略，我們可以清楚地整體情況：鎳鈦合金再灌注裝置仍然是現代血管治療的核心，但其成功需要產品設計、證據產生和供應鏈管理等方面的整合思考。材料科學的進步和輸送系統的改進拓展了臨床應用的可能性，而監管機構的期望和支付方的審查則要求提供可靠的長期數據並提高手術效率。因此，能夠協調技術創新、實用臨床研究和強大的供應鏈韌性的機構，將更有能力將裝置的潛力轉化為持續的臨床應用。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 鎳鈦諾血管重組器械市場（依產品類型分類）

  • 球囊擴張型支架
    • 冠狀動脈支架
    • 末梢用支架
  • 自膨式鎳鈦合金支架
    • 神經血管支架
    • 末梢用支架

9. 依應用分類的鎳鈦諾血管重組器械市場

  • 冠狀動脈疾病
  • 神經血管
  • 周邊動脈疾病
    • 膝蓋以下
    • 股膕動脈
    • 髂股動脈

第10章 依最終用戶分類的鎳鈦諾血管重組器械市場

  • 門診手術中心
  • 醫院
  • 專科診所

11. 鎳鈦諾血管重組器械市場（按地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第12章 鎳鈦諾血管重組器械市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

13. 各國鎳鈦諾血管重組器械市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

14. 美國鎳鈦合金血管重組器械市場

第15章 中國鎳鈦合金血管重組器械市場

第16章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • Admedes Schuessler GmbH
  • AngioDynamics, Inc.
  • Becton, Dickinson and Company
  • Bentley InnoMed GmbH
  • Biotronik SE & Co. KG
  • Boston Scientific Corporation
  • CR Bard, Inc.
  • Cook Medical LLC
  • Edwards Lifesciences Corporation
  • Elixir Medical Corporation
  • ELLA-CS
  • Endologix, Inc.
  • Johnson & Johnson
  • JOTEC GmbH
  • Lombard Medical, Inc.
  • Medtronic plc
  • Merit Medical Systems, Inc.
  • MicroPort NeuroTech
  • Nipro Corporation
  • Penumbra, Inc.
  • Stryker Corporation
  • Terumo Corporation
  • WL Gore & Associates, Inc.
Product Code: MRR-4F7A6D4FD8AF

The Nitinol Revascularization Device Market was valued at USD 2.04 billion in 2025 and is projected to grow to USD 2.26 billion in 2026, with a CAGR of 11.01%, reaching USD 4.25 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.04 billion
Estimated Year [2026] USD 2.26 billion
Forecast Year [2032] USD 4.25 billion
CAGR (%) 11.01%

A strategic primer on nitinol revascularization devices outlining clinical roles, material advantages, and the critical factors shaping clinical adoption

Nitinol revascularization devices have evolved from niche solutions into central tools across diverse vascular specialties, driven by unique material properties and continuous device innovation. Shape memory and superelasticity enable designs that conform to complex anatomies, which in turn have broadened clinical indications from coronary interventions to neurovascular and peripheral applications. As a result, clinicians and procurement teams increasingly evaluate device selection through a combined lens of deliverability, radial strength, conformability, and long-term vessel interaction.

Alongside clinical performance, regulatory scrutiny and reimbursement environments are influencing how new iterations move from concept to clinic. Advances in imaging, deployment systems, and adjunctive therapies are converging to reduce procedural times and improve lesion coverage, which incentivizes adoption among interventional cardiology, neurointerventional, and vascular surgery teams. Consequently, stakeholders must balance procedural benefits against capital and disposable costs, while anticipating evolving clinical evidence that redefines best practices.

Moving forward, the introduction of novel alloy formulations, refined surface treatments, and integrated delivery platforms will determine which products gain traction. Strategic leaders should therefore view nitinol revascularization devices not merely as consumables but as technology platforms that interact with clinical workflows, training needs, and long-term patient outcomes.

How converging technological advances clinical evidence requirements and value-based payment signals are reshaping adoption and innovation of nitinol device portfolios

The landscape for nitinol revascularization devices is undergoing transformative shifts driven by technological convergence, shifting clinical guidelines, and a renewed focus on cost-effectiveness. Miniaturization and improved delivery systems are enabling access to previously challenging anatomies, while surface engineering and drug-eluting strategies are narrowing the performance gap between self-expanding and balloon-expandable formats. These technical advances are altering clinician preference hierarchies and opening new procedural approaches that were not feasible a few years ago.

Concurrently, regulatory frameworks in multiple jurisdictions are emphasizing real-world evidence and post-market surveillance, prompting manufacturers to invest more heavily in registries and longitudinal studies. This emphasis on longitudinal data is shaping device lifecycles and market entry strategies, with an increased premium on predictable clinical outcomes. Payer policies are also evolving to reward demonstrable value, thereby aligning commercial success with quantifiable improvements in patient outcomes and procedural efficiency.

In addition, patient-centered care models and multidisciplinary treatment teams are promoting integrated solutions that combine device design with procedural training, remote monitoring, and bundled payment pilot programs. As a consequence, successful companies are those that blend engineering excellence with clinical partnerships, evidence generation, and end-user education to achieve durable adoption.

The cumulative operational and procurement impacts of the 2025 United States tariff actions that are forcing supply chain redesign and commercial reprioritization

United States tariff measures implemented in 2025 introduced a new dimension of commercial risk and operational recalibration for manufacturers and purchasers of nitinol revascularization devices. The most immediate consequence has been a reassessment of procurement strategies as organizations weigh the trade-offs between cost, continuity of supply, and the regulatory complexity of alternative sources. Many stakeholders responded by accelerating supplier qualification processes and diversifying procurement to reduce single-source dependencies, which in turn increased the emphasis on supplier audits and quality-certification alignment.

Manufacturers have re-evaluated production footprints in response, considering partial nearshoring, increased local assembly, or contractual commitments with regional manufacturing partners to mitigate tariff exposure. These moves have consequences for lead times, inventory models, and capital allocation; firms that can adapt manufacturing and distribution models while preserving quality standards are gaining competitive resilience. Meanwhile, trading partners and component suppliers adjusted commercial terms and delivery schedules to retain business, which required active negotiation and contractual flexibility.

From a demand perspective, healthcare systems have become more rigorous in tender specifications, incorporating total-cost-of-ownership considerations that include tariff-influenced logistics and warranty impacts. The net effect is an industry-wide push toward supply chain transparency, scenario planning, and strategic collaboration between purchasers and manufacturers to stabilize access to critical nitinol technologies.

Segmentation-driven implications for product development clinical adoption and procurement that connect device class application targets and end-user settings to strategic priorities

Understanding segmentation is essential for tailoring clinical, commercial, and regulatory strategies across the nitinol revascularization landscape. Product differentiation begins with two primary device classes: balloon expandable stents and self-expanding nitinol stents. Balloon expandable stents are predominantly used in coronary interventions and in peripheral applications where radial rigidity and precise deployment are paramount, while self-expanding nitinol stents serve neurovascular indications and peripheral anatomies that demand flexibility and chronic conformability. Within the peripheral category, anatomical and biomechanical distinctions between below-the-knee, femoropopliteal, and iliofemoral segments influence device design choices, longevity expectations, and procedural adjuncts.

Application-driven segmentation further clarifies clinical value propositions. Coronary artery disease treatment emphasizes deliverability in tortuous vessels and optimal scaffold support, neurovascular use cases prioritize atraumatic profiles and radiopacity for intracranial navigation, and peripheral artery disease treatment requires nuanced strategies depending on lesion location and patient mobility. Below-the-knee lesions demand fine-caliber devices that withstand flexion, femoropopliteal territories require resistance to external compression and torsion, and iliofemoral segments benefit from stents that balance large-vessel radial strength with conformability.

End-user segmentation also ensures deployment strategies match clinical settings. Ambulatory surgical centers, hospitals, and specialty clinics have differing procedural volumes, resource availability, and procurement cycles, which affects device selection, inventory management, and training investments. Recognizing how product type, clinical application, and care setting intersect enables more precise commercialization, clinical evidence planning, and education programs tailored to user-specific needs.

How regional regulatory environments clinical practice patterns and infrastructure realities across the Americas EMEA and Asia-Pacific dictate tailored commercialization approaches

Regional dynamics materially shape regulatory pathways, clinical adoption, and commercialization strategies for nitinol revascularization devices across global markets. In the Americas, regulatory frameworks are well established and payers increasingly tie reimbursement to robust clinical outcomes and cost-effectiveness, prompting manufacturers to prioritize high-quality evidence generation and streamlined distribution partnerships. Investment in training and procedural support is often decisive in building clinician confidence and pathway integration across both cardiology and vascular surgery communities.

In Europe Middle East and Africa, heterogeneous regulatory environments and variable healthcare infrastructure create both opportunities and complexities. Manufacturers often adopt regionally nuanced market entry strategies that combine CE or notified body approvals with country-specific evidence generation, while strategic partnerships with regional distributors and clinical centers accelerate adoption in capacity-constrained environments. Reimbursement variability in this region means that demonstrating clear clinical benefit and procedural efficiency is frequently more important than price alone.

In Asia-Pacific, rapid modernization of healthcare infrastructure, high procedural volumes, and a growing emphasis on domestic manufacturing capacity are driving significant activity. Regulatory agencies across the region are increasingly aligning to international standards while encouraging local trials and post-market surveillance. For many companies, Asia-Pacific represents both a testing ground for scalable innovations and a focal point for manufacturing and supply-chain investments aimed at global resilience.

Competitive and collaborative company-level perspectives focusing on technological differentiation evidence partnerships and operational capabilities that shape market positioning

Competitive dynamics among companies in the nitinol revascularization space are defined by differentiated approaches to innovation, clinical partnership, and go-to-market execution. Some manufacturers emphasize platform engineering, integrating next-generation delivery systems with advanced imaging compatibility to deliver incremental clinical improvements and procedural efficiencies. Others prioritize surface treatments, drug-eluting technologies, and polymer integration to address restenosis and long-term vessel healing, which requires sustained investment in clinical trials and post-market surveillance.

Collaborative models are gaining traction as well, where established device firms form alliances with startup innovators, imaging companies, and academic centers to accelerate translational research and shorten development cycles. Strategic M&A and licensing deals are used to fill technological gaps, expand anatomical coverage, or access regional distribution networks. Meanwhile, companies that invest in robust clinical education programs and center-of-excellence collaborations tend to achieve faster procedural uptake and longer-term clinician advocacy.

Quality systems and regulatory acumen remain differentiators; firms that maintain transparent supply chains, proactive vigilance systems, and disciplined regulatory submissions reduce approval friction and strengthen customer trust. Ultimately, success is achieved by balancing engineering differentiation with evidence generation, manufacturing reliability, and end-user support.

Actionable strategies for manufacturers health systems and distributors to build resilient supply chains accelerate clinical adoption and demonstrate payer-relevant value

Industry leaders should pursue a set of pragmatic actions to translate insight into competitive advantage across clinical, commercial, and operational domains. First, prioritize modular platform development that allows a single delivery system to support multiple nitinol geometries and therapeutic indications, thereby reducing manufacturing complexity and easing clinician training burdens. Second, invest in targeted real-world evidence programs and registries that address the most pressing payer questions and generate longitudinal safety data needed for durable reimbursement conversations.

Third, redesign procurement and supply-chain strategies to incorporate tariff sensitivity, dual sourcing, and regional assembly options that reduce exposure to policy shifts and logistics disruptions. Fourth, align commercialization efforts with specific end-user workflows by offering procedure-centric training, simulation, and hands-on proctoring that demonstrably shorten learning curves and improve outcomes. Fifth, establish strategic partnerships with imaging and analytics providers to create integrated procedural ecosystems that enhance device value and create stickiness with clinical customers.

Collectively, these measures strengthen resilience, accelerate adoption, and protect margins. Executed together, they enable organizations to respond to regulatory change, demonstrate value to payers, and preserve access for clinicians and patients.

A transparent and replicable methodological framework combining literature synthesis expert interviews and supply-chain analysis to validate insights and implications

The research underpinning this analysis used a mixed-methods approach to ensure robustness, triangulation, and transparency. Secondary data collection included peer-reviewed clinical literature, regulatory filings, and device clearance summaries to map clinical evidence and approval pathways. Patent landscaping and product labeling reviews were used to identify technological differentiators and claims substantiation, while public procurement documents and hospital purchasing policies informed pricing and tender considerations.

Primary research incorporated structured interviews with practicing interventionalists, vascular surgeons, procurement leaders, and regulatory experts to validate clinical priorities and device selection criteria. Manufacturer discussions and supply-chain conversations provided operational insight into manufacturing constraints, qualification timelines, and logistics. Data synthesis prioritized cross-validation; where secondary signals suggested a trend, primary respondents were consulted to confirm practical implications and timing. Analytical steps included thematic coding of qualitative inputs, comparative device feature matrices, and scenario analysis for tariff and supply disruption impacts.

Quality assurance processes included independent peer review by clinical and industry advisors, audit trails for sourced documents, and consistency checks across datasets to minimize bias. The methodology emphasizes replicability and clear documentation, enabling stakeholders to trace findings back to source evidence and expert corroboration.

Synthesis of clinical technological and commercial forces that determine which nitinol devices will achieve durable adoption and strategic advantage

Bringing together clinical evolution, policy headwinds, and commercial strategy yields a cohesive picture: nitinol revascularization devices remain central to contemporary vascular care, but success requires integrated thinking across product design, evidence generation, and supply-chain management. Material science advances and delivery-system refinements expand clinical possibilities, yet regulatory expectations and payer scrutiny mandate credible long-term data and procedural efficiency gains. Consequently, organizations that synchronize engineering innovation with pragmatic clinical studies and robust supply resilience will be best positioned to translate device potential into sustained clinical adoption.

Regional nuances and end-user requirements underscore the need for adaptable commercialization models: what succeeds in high-volume tertiary centers may not transfer directly to ambulatory or specialty clinic settings without tailored training and evidence. Tariff-driven supply shocks in 2025 crystallized the importance of diversified sourcing and flexible manufacturing footprints, accelerating strategic shifts that were already under way. Moving forward, the convergence of integrated procedural ecosystems, real-world evidence, and patient-centered outcomes will determine which products achieve scale.

Ultimately, the path to leadership in the nitinol device space lies in balancing technical differentiation with operational excellence, aligning product roadmaps with payer expectations, and maintaining close clinical partnerships that drive repeatable, measurable improvements in care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Nitinol Revascularization Device Market, by Product Type

  • 8.1. Balloon Expandable Stent
    • 8.1.1. Coronary Stent
    • 8.1.2. Peripheral Stent
  • 8.2. Self Expanding Nitinol Stent
    • 8.2.1. Neurovascular Stent
    • 8.2.2. Peripheral Stent

9. Nitinol Revascularization Device Market, by Application

  • 9.1. Coronary Artery Disease
  • 9.2. Neurovascular
  • 9.3. Peripheral Artery Disease
    • 9.3.1. Below The Knee
    • 9.3.2. Femoropopliteal
    • 9.3.3. Iliofemoral

10. Nitinol Revascularization Device Market, by End User

  • 10.1. Ambulatory Surgical Centers
  • 10.2. Hospitals
  • 10.3. Specialty Clinics

11. Nitinol Revascularization Device Market, by Region

  • 11.1. Americas
    • 11.1.1. North America
    • 11.1.2. Latin America
  • 11.2. Europe, Middle East & Africa
    • 11.2.1. Europe
    • 11.2.2. Middle East
    • 11.2.3. Africa
  • 11.3. Asia-Pacific

12. Nitinol Revascularization Device Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Nitinol Revascularization Device Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. United States Nitinol Revascularization Device Market

15. China Nitinol Revascularization Device Market

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025
  • 16.5. Abbott Laboratories
  • 16.6. Admedes Schuessler GmbH
  • 16.7. AngioDynamics, Inc.
  • 16.8. Becton, Dickinson and Company
  • 16.9. Bentley InnoMed GmbH
  • 16.10. Biotronik SE & Co. KG
  • 16.11. Boston Scientific Corporation
  • 16.12. C. R. Bard, Inc.
  • 16.13. Cook Medical LLC
  • 16.14. Edwards Lifesciences Corporation
  • 16.15. Elixir Medical Corporation
  • 16.16. ELLA-CS
  • 16.17. Endologix, Inc.
  • 16.18. Johnson & Johnson
  • 16.19. JOTEC GmbH
  • 16.20. Lombard Medical, Inc.
  • 16.21. Medtronic plc
  • 16.22. Merit Medical Systems, Inc.
  • 16.23. MicroPort NeuroTech
  • 16.24. Nipro Corporation
  • 16.25. Penumbra, Inc.
  • 16.26. Stryker Corporation
  • 16.27. Terumo Corporation
  • 16.28. W. L. Gore & Associates, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL NITINOL REVASCULARIZATION DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL NITINOL REVASCULARIZATION DEVICE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL NITINOL REVASCULARIZATION DEVICE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. UNITED STATES NITINOL REVASCULARIZATION DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 11. CHINA NITINOL REVASCULARIZATION DEVICE MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL NITINOL REVASCULARIZATION DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY BALLOON EXPANDABLE STENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY BALLOON EXPANDABLE STENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY BALLOON EXPANDABLE STENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY BALLOON EXPANDABLE STENT, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY CORONARY STENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY CORONARY STENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY CORONARY STENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY PERIPHERAL STENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY PERIPHERAL STENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY PERIPHERAL STENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY SELF EXPANDING NITINOL STENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY SELF EXPANDING NITINOL STENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY SELF EXPANDING NITINOL STENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY SELF EXPANDING NITINOL STENT, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY NEUROVASCULAR STENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY NEUROVASCULAR STENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY NEUROVASCULAR STENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY PERIPHERAL STENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY PERIPHERAL STENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY PERIPHERAL STENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY CORONARY ARTERY DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY CORONARY ARTERY DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY CORONARY ARTERY DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY NEUROVASCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY NEUROVASCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY NEUROVASCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY BELOW THE KNEE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY BELOW THE KNEE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY BELOW THE KNEE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY FEMOROPOPLITEAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY FEMOROPOPLITEAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY FEMOROPOPLITEAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY ILIOFEMORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY ILIOFEMORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY ILIOFEMORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. AMERICAS NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 55. AMERICAS NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 56. AMERICAS NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY BALLOON EXPANDABLE STENT, 2018-2032 (USD MILLION)
  • TABLE 57. AMERICAS NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY SELF EXPANDING NITINOL STENT, 2018-2032 (USD MILLION)
  • TABLE 58. AMERICAS NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 59. AMERICAS NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 60. AMERICAS NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 61. NORTH AMERICA NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. NORTH AMERICA NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 63. NORTH AMERICA NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY BALLOON EXPANDABLE STENT, 2018-2032 (USD MILLION)
  • TABLE 64. NORTH AMERICA NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY SELF EXPANDING NITINOL STENT, 2018-2032 (USD MILLION)
  • TABLE 65. NORTH AMERICA NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 66. NORTH AMERICA NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 67. NORTH AMERICA NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 68. LATIN AMERICA NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. LATIN AMERICA NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 70. LATIN AMERICA NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY BALLOON EXPANDABLE STENT, 2018-2032 (USD MILLION)
  • TABLE 71. LATIN AMERICA NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY SELF EXPANDING NITINOL STENT, 2018-2032 (USD MILLION)
  • TABLE 72. LATIN AMERICA NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 73. LATIN AMERICA NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 74. LATIN AMERICA NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE, MIDDLE EAST & AFRICA NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE, MIDDLE EAST & AFRICA NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPE, MIDDLE EAST & AFRICA NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY BALLOON EXPANDABLE STENT, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY SELF EXPANDING NITINOL STENT, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY BALLOON EXPANDABLE STENT, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY SELF EXPANDING NITINOL STENT, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 89. MIDDLE EAST NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. MIDDLE EAST NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. MIDDLE EAST NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY BALLOON EXPANDABLE STENT, 2018-2032 (USD MILLION)
  • TABLE 92. MIDDLE EAST NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY SELF EXPANDING NITINOL STENT, 2018-2032 (USD MILLION)
  • TABLE 93. MIDDLE EAST NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 94. MIDDLE EAST NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 95. MIDDLE EAST NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 96. AFRICA NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. AFRICA NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. AFRICA NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY BALLOON EXPANDABLE STENT, 2018-2032 (USD MILLION)
  • TABLE 99. AFRICA NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY SELF EXPANDING NITINOL STENT, 2018-2032 (USD MILLION)
  • TABLE 100. AFRICA NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 101. AFRICA NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 102. AFRICA NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY BALLOON EXPANDABLE STENT, 2018-2032 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY SELF EXPANDING NITINOL STENT, 2018-2032 (USD MILLION)
  • TABLE 107. ASIA-PACIFIC NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 108. ASIA-PACIFIC NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. ASEAN NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. ASEAN NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. ASEAN NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY BALLOON EXPANDABLE STENT, 2018-2032 (USD MILLION)
  • TABLE 114. ASEAN NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY SELF EXPANDING NITINOL STENT, 2018-2032 (USD MILLION)
  • TABLE 115. ASEAN NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 116. ASEAN NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 117. ASEAN NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 118. GCC NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GCC NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. GCC NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY BALLOON EXPANDABLE STENT, 2018-2032 (USD MILLION)
  • TABLE 121. GCC NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY SELF EXPANDING NITINOL STENT, 2018-2032 (USD MILLION)
  • TABLE 122. GCC NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 123. GCC NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 124. GCC NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPEAN UNION NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPEAN UNION NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPEAN UNION NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY BALLOON EXPANDABLE STENT, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPEAN UNION NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY SELF EXPANDING NITINOL STENT, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPEAN UNION NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPEAN UNION NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPEAN UNION NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. BRICS NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. BRICS NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. BRICS NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY BALLOON EXPANDABLE STENT, 2018-2032 (USD MILLION)
  • TABLE 135. BRICS NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY SELF EXPANDING NITINOL STENT, 2018-2032 (USD MILLION)
  • TABLE 136. BRICS NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 137. BRICS NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 138. BRICS NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 139. G7 NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. G7 NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. G7 NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY BALLOON EXPANDABLE STENT, 2018-2032 (USD MILLION)
  • TABLE 142. G7 NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY SELF EXPANDING NITINOL STENT, 2018-2032 (USD MILLION)
  • TABLE 143. G7 NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 144. G7 NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 145. G7 NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 146. NATO NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. NATO NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. NATO NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY BALLOON EXPANDABLE STENT, 2018-2032 (USD MILLION)
  • TABLE 149. NATO NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY SELF EXPANDING NITINOL STENT, 2018-2032 (USD MILLION)
  • TABLE 150. NATO NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 151. NATO NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 152. NATO NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. UNITED STATES NITINOL REVASCULARIZATION DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 155. UNITED STATES NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. UNITED STATES NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY BALLOON EXPANDABLE STENT, 2018-2032 (USD MILLION)
  • TABLE 157. UNITED STATES NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY SELF EXPANDING NITINOL STENT, 2018-2032 (USD MILLION)
  • TABLE 158. UNITED STATES NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 159. UNITED STATES NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 160. UNITED STATES NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. CHINA NITINOL REVASCULARIZATION DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 162. CHINA NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. CHINA NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY BALLOON EXPANDABLE STENT, 2018-2032 (USD MILLION)
  • TABLE 164. CHINA NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY SELF EXPANDING NITINOL STENT, 2018-2032 (USD MILLION)
  • TABLE 165. CHINA NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 166. CHINA NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 167. CHINA NITINOL REVASCULARIZATION DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)